Brief: Innate Pharma Nine-Months Revenue Down At 33.6 Million Euros

Innate Pharma SA

17/11/2020 06:08

Nov 17 (Reuters) - INNATE PHARMA SA  IPH.PA :
    * INNATE PHARMA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS
AND
BUSINESS UPDATE
    * MONALIZUMAB PHASE 3 STUDY INITIATED, TRIGGERING $50
MILLION
MILESTONE PAYMENT
    * LACUTAMAB GRANTED PRIME DESIGNATION IN SÉZARY SYNDROME BY
EUROPEAN MEDICINES AGENCY
    * CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY
AMOUNTED
TO EUR 163.6 MILLION AS OF SEPTEMBER 30, 2020
    * REVENUES FOR FIRST NINE-MONTHS OF 2020 AMOUNTED TO EUR
33.6
MILLION, COMPARED TO EUR 65.4 MILLION FOR SAME PERIOD IN 2019

Source text for Eikon:  ID:nGNE9PDmX4 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))